- Rentschler Biopharma marked the progress of its Milford, Massachusetts site, where a new manufacturing line is now fully operational.
Rentschler Biopharma SE has highlighted the continued development of its Milford, Massachusetts site, marking the site’s evolution into a multi-product manufacturing facility within its global CDMO network.
The company held a celebration event under the theme “Together We Build” to recognize the site’s progress and its role in supporting biopharmaceutical manufacturing. The Milford facility has been transformed since 2019, with the newest manufacturing line now fully operational and supporting a growing number of client projects.
The new production line, which became operational in 2024, represents the largest expansion in the company’s more than 150-year history. It adds 22,000 square feet of manufacturing cleanroom space and includes four 2,000 L single-use bioreactors, expanding global cGMP capacity and enabling support for late-stage and commercial programs.
Rentschler Biopharma stated that the Milford site plays an important role in its U.S. strategy, enabling continuity from early development through commercial supply. Over the past two years, seven new products have been introduced at the site, including programs in or post process performance qualification (PPQ).
“At Rentschler Biopharma, we are committed to advancing medicine to save lives – together. ‘Together We Build’ reflects how we support our clients by delivering reliably at every step of their molecule’s journey.”
Uwe Buecheler, interim CEO of Rentschler Biopharma
